Bindu Balani, M.D.
Associate Member, Center for Discovery and Innovation
Associate Professor of Medicine
Senior Infectious Disease Consultant at Hackensack Meridian School of Medicine
Dr. Bindu Balani is an Associate Professor of Medicine and a Senior Infectious Disease Consultant at Hackensack Meridian School of Medicine. With a distinguished career in both education and clinical practice, Dr. Balani is dedicated to fostering integrative knowledge and developing critical problem-solving skills in students and residents. She has a proven track record of mentoring the next generation of healthcare leaders while advancing infection prevention strategies and improving patient care outcomes. Dr. Balani is also skilled in curricular innovation and program funding acquisition, blending educational leadership with clinical expertise. Academically, she is actively involved in clinical research and has authored several publications in peer-reviewed journals.
Selected Publications
- Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.
Fusco D, Malenica I, Günthard HF, Gupta SK, Kurbegov D, Balani B, Olender S, Aberg JA, Telep LE, Tian Y, Blair C, Wu G, Haubrich RH, Wang CY, Chokkalingam AP, Osinusi AO, Wendtner CM, Gottlieb RL.
Clin Infect Dis. 2024
PMID: 38920297
- Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
Donato ML, Park S, Baker M, Korngold R, Morawski A, Geng X, Tan M, Ip A, Goldberg S, Rowley S, Chow K, Brown E, Zenreich J, McKiernan P, Buttner K, Ullrich A, Long L, Feinman R, Ricourt A, Kemp M, Vendivil M, Suh H, Balani B, Cicogna C, Sebti R, Al-Khan A, Sperber S, Desai S, Fanning S, Arad D, Go R, Tam E, Rose K, Sadikot S, Siegel D, Gutierrez M, Feldman T, Goy A, Pecora A, Biran N, Leslie L, Gillio A, Timmapuri S, Boonstra M, Singer S, Kaur S, Richards E, Perlin DS.
JCI Insight. 2021
PMID: 33571168
- Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.
Olender SA, Walunas TL, Martinez E, Perez KK, Castagna A, Wang S, Kurbegov D, Goyal P, Ripamonti D, Balani B, De Rosa FG, De Wit S, Kim SW, Diaz G, Bruno R, Mullane KM, Lye DC, Gottlieb RL, Haubrich RH, Chokkalingam AP, Wu G, Diaz-Cuervo H, Brainard DM, Lee IH, Hu H, Lin L, Osinusi AO, Bernardino JI, Boffito M.
Open Forum Infect Dis. 2021
PMID: 34282406
- Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection.
Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C, Bawa H, Berrol L, Qureshi N, Aschner JL.
PLoS One. 2020
PMID: 33306721
Active Clinical Trial Studies
- Post Treatment Lyme Study
- For COVID inpatient treatment _ ACTIV IM - STRIVE study current
- HDV screening _ current
- FOCUS screening of blood borne pathogens for HIV / HBV / HCV in the ED setting - current
- TOUR study current
- SUPERNOVA study